Literature DB >> 16531284

Downregulation of Thy1 in retinal ganglion cells in experimental glaucoma.

Wei Huang1, John Fileta, Yan Guo, Cynthia L Grosskreutz.   

Abstract

PURPOSE: Thy1 is a surface glycoprotein uniquely expressed in retinal ganglion cells (RGCs) in retina. The aim of this study was to investigate the expression change of Thy1 in a model of experimental glaucoma.
METHODS: The change of protein and mRNA levels of Thy1 in the retina were studied using stereological counts of back-labeled RGCs, Western blot analysis, immunohistochemistry, and laser capture microdissection (LCM) of RGCs with quantitative PCR analysis of mRNA in a model of experimental glaucoma. LCM after optic nerve crush was also performed to evaluate Thy1 mRNA levels after a different injury.
RESULTS: After 10 days of elevated IOP, there was a 34% loss of RGC number, Thy1 protein decreased 60% in eyes with elevated intraocular pressure (IOP), and Thy1 mRNA levels decreased 51% in RGCs. Both protein and mRNA level change of Thy1 is to a much greater extent than RGC number loss.
CONCLUSIONS: The current results confirm that Thy 1 mRNA levels do not reflect the number of RGCs present and extend this to include a parallel decrease in Thy1 protein levels. These results suggest that Thy1 serves as an early marker of RGC stress, but not a marker of RGC loss, in models of retinal damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16531284     DOI: 10.1080/02713680500545671

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  50 in total

1.  Global gene expression changes in rat retinal ganglion cells in experimental glaucoma.

Authors:  Dan Yi Wang; Arjun Ray; Kathryn Rodgers; Ceren Ergorul; Bradley T Hyman; Wei Huang; Cynthia L Grosskreutz
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-24       Impact factor: 4.799

2.  The cell and molecular biology of glaucoma: mechanisms of retinal ganglion cell death.

Authors:  Robert W Nickells
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-04       Impact factor: 4.799

3.  Longitudinal profile of retinal ganglion cell damage after optic nerve crush with blue-light confocal scanning laser ophthalmoscopy.

Authors:  Christopher Kai-shun Leung; James D Lindsey; Jonathan G Crowston; Chen Lijia; Sylvia Chiang; Robert N Weinreb
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-25       Impact factor: 4.799

4.  Neurotrophic effect of a novel TrkB agonist on retinal ganglion cells.

Authors:  Ying Hu; Seongeun Cho; Jeffrey L Goldberg
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-29       Impact factor: 4.799

5.  A nicotinic acetylcholine receptor agonist prevents loss of retinal ganglion cells in a glaucoma model.

Authors:  Kazuhiro Iwamoto; Patrick Birkholz; Austin Schipper; David Mata; David M Linn; Cindy L Linn
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-24       Impact factor: 4.799

6.  Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies.

Authors:  Natalie D Bull; Thomas V Johnson; Guncha Welsapar; Nicholas W DeKorver; Stanislav I Tomarev; Keith R Martin
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-17       Impact factor: 4.799

Review 7.  Evaluating retinal ganglion cell loss and dysfunction.

Authors:  Ben Mead; Stanislav Tomarev
Journal:  Exp Eye Res       Date:  2016-08-12       Impact factor: 3.467

8.  Nuclear atrophy of retinal ganglion cells precedes the bax-dependent stage of apoptosis.

Authors:  Katherine T Janssen; Caitlin E Mac Nair; Joel A Dietz; Cassandra L Schlamp; Robert W Nickells
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-11       Impact factor: 4.799

Review 9.  Neurotrophin roles in retinal ganglion cell survival: lessons from rat glaucoma models.

Authors:  Elaine C Johnson; Ying Guo; William O Cepurna; John C Morrison
Journal:  Exp Eye Res       Date:  2009-02-14       Impact factor: 3.467

10.  Changes in ocular aquaporin expression following optic nerve crush.

Authors:  Adnan Dibas; Hidehiro Oku; Masayuki Fukuhara; Takuji Kurimoto; Tsunehiko Ikeda; Rajkumar V Patil; Najam A Sharif; Thomas Yorio
Journal:  Mol Vis       Date:  2010-03-03       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.